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Aim: Review of main SBRT features and indications in primary tumors.
Background: Stereotactic body radiotherapy has been developed in the last few years. SBRT
allows the hypofractionated treatment of extra cranial tumors, using either a single or
limited number of dose fractions, and resulting in the delivery of a high biological effective
dose with low toxicity.
Material and methods: SBRT requires a high level of accuracy for all phases of the treatment
process: effective patient immobilization, precise target localization, highly conformed
dosimetry and image guided systems for treatment veriﬁcation. The implementation of
SBRT  in routine requires a careful considering of organ motion. Gating and tracking are
effective ways to do so, and less invasive technologies “ﬁducials free” have been developed.
Due  to the hypofractionated scheme, the physician must pay attention to new dosimetric
constraints in organ at risk and new radiobiological models are needed to assess the optimal
fractionation and dose schemes.
Results: Currently, SBRT is safe and effective to treat primary tumors, which are otherwise
untreatable with conventional radiotherapy or surgery. SBRT has quickly developed because
of  its excellent results in terms of tolerance and its high locoregional control rates. SBRT indi-
cations in primary tumors, such as lung primary tumors, have become a standard of care for
inoperable patients. SBRT seems to be effective in many others indications in curative or pal-
liative intent such as liver primary tumors, and novel indications and strategies are currently
emerging in prostate cancer, head and neck tumor recurrences or pelvis reirradiations.
Conclusion: Currently, SBRT is mainly used when there is no other therapeutic alternativefor  the patient. This is due to the lack of randomized trials in these settings. However, theresults shown in retrospec
for  many patients in the n
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1.  SBRT  overview  and  requirements
Over the last decades stereotactic cranial radiosurgery has
been successfully used for the treatment of intracranial
lesions as it can precisely deliver a high dose of radiation to
a tumor with very low dose to surrounding critical tissues.
The good results obtained in intra-cranial localizations have
led to the development of extra-cranial stereotactic radiation
therapy known as stereotactic body radiation therapy (SBRT).
SBRT, as a precise external beam radiation technique, allows
the hypofractionated treatment of extra cranial tumors, using
either a single or limited number of dose fractions, and result-
ing in the delivery of a high biological effective dose, often
above 100 Gy which could be considered as “ablative” dose
(stereotactic ablative body radiotherapy “SABR” is another sug-
gested name for this technique). As in intracranial stereotactic
radiosurgery, SBRT requires a high level of accuracy for all
phases of the treatment process and organ and patient motion
must be considered in the treatment planning. Recommenda-
tions and treatment quality control guidelines have also been
established for SBRT.1,2
Accuracy in SBRT requires effective patient immobiliza-
tion, precise target localization with the integration of modern
image systems (CT, MRI, PET-CT) in order to properly deﬁne
the tumor area for treatment and to further minimize radia-
tion dose to healthy surrounding tissues; treatment planning
also requires highly conformed dosimetry and isotropic dose
fall-off (Fig. 1). Dose calculations should be carried out with
algorithms which can account for the effects of tissue hetero-
geneities. Therefore, in order to deliver these accurate doses,
linear accelerators must be equipped with micromultileaf col-
limators, the possibility of using multiple non overlapping
beams of radiation and even intensity modulated radiation
therapy.
One of the key challenges and requirements of SBRT is
to reach the same “stereotactic accuracy” for extra cranial
treatment as is achieved for cranial treatments. SBRT requires
new image-guided veriﬁcation techniques (IGRT), such as cone
beam imaging or stereoscopic X-ray imaging, that allow a pre-
cise treatment of non-moving lesions (spine, prostate, etc.).
For moving lesions such as lung and liver tumors, problems
with accuracy still remain a challenge, and the assessment
Fig. 1 – SBRT treatment for early stage peripheral NSCL cancer. H
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of tumor motion can be approached in different ways. Quan-
tiﬁcation of tumor motion can be measured and an ITV
(internal target volume) can be deduced using a 4D-CT scan
during the different respiratory phases. To reduce the tar-
get treatment area and spare healthy tissue more  effectively,
restrictive techniques, such as “dampening” with abdominal
compression, can be used. Other methods called “compensat-
ing techniques” can not only quantify tumor motion but also
have an intra-fraction control of tumor position and can treat
the tumor exactly at the place where it is located, by visualiz-
ing its motion during the treatment. These techniques allow
a precise delivery of high dose of radiation to the tumor with
minimal dose to surrounding critical tissue (Fig. 1).
Novalis Exactrac Adaptive Gating® technique has been
developed as a method that improves the accuracy of SBRT for
lung and liver lesions, by monitoring organ tumor motion and
irradiating within a selected area of the respiratory cycle. The
tumor can be irradiated in this selected area by using internal
markers previously implemented close to or directly into the
tumor. Based on external markers, internal tumor motion is
correlated with the external respiratory signal. During patient
setup, infrared markers track the respiratory cycle. The Exac-
trac image  guided system localizes the internal marker by
X-rays and quantiﬁes the tumor motion by correlating the
external marker motion to the internal marker position. A
selected area of this cycle is deﬁned as the “beam on area”
of irradiation. The validity of this model is veriﬁed in real time
by ExacTrac X-Rays3,4 (Fig. 2).
“Tracking” is another compensating technique, and the
tumor can be followed by “tracking” these ﬁducials or even
by tracking certain tumors visible in the guidance X-ray image
system. The CyberKnife system can track the tumor during
the treatment using ﬁducials. However, transthoracic ﬁducials
implantation under CT guidance can be responsible for pneu-
mothorax (24–45%).5,6 A ﬁducial-free tracking system, Xsight®
Lung Tracking System (XLTS), has therefore been designed.
This system requires that the tumor is wider than 15 mm and
that it is visible in the orthogonal X-ray images (the tumor
must be distant of at least 15 mm from any major vascular
structures and its projection on the spine must be different
from 45◦). The system also uses a correlation model between
external markers and the internal tumor positions to attain a
millimetric precision. Both tracking systems can be combined
ighly conformed dosimetry with multiple beams. Dose
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Fig. 2 – Organ motion compensating technique example: Novalis® Exactrac Adaptive Gating SBRT for lung and liver lesions.
Monitoring organ tumor motion and irradiation within a selected area of the respiratory cycle with Exactrac image guide
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ith the Synchrony Respiratory Tracking System in order to
ynchronize the beam targeting with the respiratory cycle.7
All these compensating techniques reduce the treated vol-
me  and the dose to the normal tissue. Therefore, accuracy in
ll phases of SBRT procedure is absolutely required in order to
ive effective and safe treatments with high and doses to the
umor and low risk of toxicity for the patient.
.  SBRT  for  primary  lung  tumors
on small cell lung cancer (NSCLC) is a leading cause of can-
er death in the world. Approximately 20% of patients are
iagnosed with stage I, and surgery is the standard treat-
ent for them with overall survival rates of 60–70%.8,9 Surgical
obectomy may be associated with signiﬁcant morbidity and
ortality, and up to 25% of the patients cannot be operated
ue to a poor pulmonary function or comorbidities. With
he wait and see policy, the overall median survival of these
atients is only 9 months. Surgery is associated with the dete-
ioration of quality of life, and in order to reduce its morbidity
nd risks of mortality, video-assisted thoracic surgery (VATS)
as also been proposed.10,11
Until recently, for non operable stage I NSCLC, conventional
adiotherapy (3D-CRT) has been the treatment of choice reach-
ng local recurrence rates of 40% and speciﬁc survival of 39%
t 3 years.12
Other alternatives, as radiofrequency ablation (RFA), have
een explored for the treatment of patients who are not candi-
ates for surgery on the basis of age, underlying lung disease,
r other medical comorbidities. RFA works by transferring
adiofrequency energy from a generator through an electrode,
ausing coagulation and necrosis of the tumor. The results of
he published studies indicate the best results are achievedin small lesions (≤3 cm). Median survival of patients receiv-
ing RFA ranged from 8.6 months to 33 months, 1 year survival
rate ranged from 63 to 85% and 3 year survival rate ranged
from 15 to 46%. The 1–3 year local tumor progression-free rates
were 45–83% and 25–57%, respectively. The adverse effects
associated with RFA include pneumothorax (28–49%), pleural
effusion, hemoptysis or pain.13,14
SBRT offers the possibility to treat these patients efﬁciently
with a minimal risk of toxicity and to escalate dose of radio-
therapy. SBRT has emerged as a new cancer therapy for the
treatment of early-stage NSCLC, showing excellent clinical
results without high costs in terms of toxicity, which has
allowed to argue that the new technique is an alternative not
only to surgery in inoperable patients, but perhaps also in
operable patients.
The cost-effectiveness of these alternatives, 3D-CRT, SBRT,
and RFA, has been analyzed. In comparison to 3D-CRT and
RFA, SBRT was the most cost-effective treatment for medically
inoperable NSCLC over a wide range of treatment and disease
assumptions, so on these basis, SBRT could be the primary
treatment approach for this disease.15
3.  Lung  SBRT  retrospective  studies
Early experience with SBRT for early stage NSCLC come from
Sweden and Japan with excellent results in local control and
survival in several retrospective studies.16–20 Perhaps the most
signiﬁcant study was a multi-institutional Japanese study
published by Onishi, including 245 patients, of whom 158
(65%) inoperable.21 The dose administered was 18–75 Gy in
1–22 fractions with an average of biological equivalent dose
(DEB) > 108 Gy. With a mean follow up of 24 months, the
overall response rate was 85% and overall survival at 3 and
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Table 1 – Selected published series of stereotactic body radiotherapy for early stage NSCLC. Retrospective and phase I–II
studies.
Author Patients Study Doses Local control Toxicity
Onishi 200421 245 Multicentric retrospective 18–75 Gy/1–22 fx 5 years 84% 7.6% grade ≥ 3
Baumann 200620 138 Multicentric retrospective 30–48 Gy/3 fx 33 months 88% 10% grade ≥ 3
McGarry 200522 47 Phase I 60–66 Gy/3 fx 15 months 79% 15% grade ≥ 3
Timmerman 200623,24 70 Phase II 60–66 Gy/3 fx 2  years 95% 20% grade ≥ 3
18 24–4
15 Gy
60 GyZimmerman 2005 68 Retrospective 
Nyman 200619 57 Phase II 
Lagerwaard 200826 206 Multicentric retrospective 
5 years was 56% and 47%, respectively. This study showed
that patients treated with SBRT with DEB > 100 Gy had bet-
ter overall survival rates, and concluded that these doses are
adequate to achieve good local control and survival in stage I
NSCL.
4.  Lung  SBRT  prospective  studies
Indiana University is one of the ﬁrst prospective studies of
SBRT for early-stage NSCLC. It is a phase I study of 47 inopera-
ble stage I (T1-T2) patients. The maximum tolerated dose was
not reached for tumors smaller than 5 cm,  reaching levels of
20–22 Gy dose × 3 (60–66 Gy).22 Based on this study, Timmer-
mann performed a phase II in 70 patients using a scheme
of 3 fractions of 20 Gy for T1 and 3 of 22 Gy for T2 tumors.23
With a median follow-up of 17.5 months, the rate of LC at
2 years was 95% and overall survival was 55%. Patients with
central tumors had a complication rate signiﬁcantly higher
than patients with peripheral tumors, with grade 5 toxicity
recorded in 6 patients. In the multivariate analysis, tumor size
also signiﬁcantly inﬂuenced the occurrence of grade 3–5 tox-
icity although it was not such a powerful predictor as tumor
location (Table 1).
This phase II study was the basis of the RTOG 0236
phase II study performed in 59 biopsy-proven peripheral
T1T2N0M0 tumors which were treated with 54 Gy in three
fractions Patients with tumors ≤2 cm from the proximal
bronchial tree were excluded. In the 55 evaluable patients,
at a median follow-up of 34 months, there were two grade
four adverse events, the 3-year primary tumor control rate
was 98%, and 3-year local control rate was 91%. The 3-
year disease-free and overall survival rates were 48 and 56%,
24respectively.
A phase I/II study (RTOG 0813, NCT00750269) evaluated
escalating doses delivered in ﬁve fractions for centrally
located tumors. The goal of that trial was to determine
Table 2 – Selected published series of stereotactic body radiothe
I–II studies.
Author Patients Study D
Blomgren 199816 11 Retrospective 30 Gy 2–5 fx 
Mendez Romero 200641 8 Prospective 25–37.5 Gy/3–5 fx 
Choi 200642 20 Prospective 50 Gy/5 fx 
Tse 200843 31 Prospective 36 Gy/6 fx 
Cardenes 200844,45 17 Prospective 36–48 Gy/3fx Chil
Dewas 201248 42 Retrospective 40–45 Gy/3 fx 
Andolino 201146 60 Retrospective 42 Gy/3 fx (Child A0 Gy/3–5 fx 3 years 88% 9% grade ≥ 3
/3 fx 3 years 92% 26% grade ≥ 3
 (3 × 20 Gy/5 × 12 Gy/8 × 7.5 Gy) 3 years 93% 6% grade ≥ 3
whether a modiﬁed schedule may minimize toxicity for cen-
trally located tumors. The starting dose was 50 Gy in ﬁve
fractions (10 Gy per fraction) with escalation to 12 Gy per
fraction for tumors located within the proximal bronchial
tree.25
In 2008, the Dutch multi-center experience in lung SBRT
was published, including a total of 206 patients who  had inop-
erable early stage SNCLC or who refused surgery.26 Only 31%
of the patients had histological conﬁrmation of malignancy.
Both central and peripheral tumors were included, using a
“risk adjusted” fractionation scheme according to size and
tumor location. Three fractions of 20 Gy were used for small
tumors, 5 fractions of 12 Gy for large tumors or those close to
chest wall and 8 fractions of 7.5 Gy for central tumors. Two
years’ results were a 93% LC, 64% OS and grade 3 late toxic-
ity ≤6%. The update of this study with 676 patients treated
between 2003 and 2011 found a median overall survival of 41
months (35–47 months) and a 5 year local control of 89%27
(Table 1).
This data from literature has already shown that SBRT can
be ﬁrmly established as a standard of care for early stage
NSCLC inoperable patients, with very high local control and
overall survival rates and relatively low morbidity.24–26
These excellent results in inoperable patients bring the
challenge to show if SBRT can also be an alternative to sur-
gical treatment in operable patients, although this question is
yet to be answered.28
There are recent data of a prospective phase II trial (RTOG
0618) of SBRT for early stage non-small cell lung cancer
in operable patients with peripheral T1-T3, N0, M0  tumors.
The prescription dose was 54 Gy (3 fractions of 18 Gy). Of 26
evaluable patients, 16% had SBRT related grade 3 toxicity.
Median follow-up was 25 months. 2-year primary tumor fail-
ure rate of 7.7%. 2-year estimates of PFS and OS are 65.4%
and 84.4%.29,11 There is at least another ongoing phase II trial
(Japanese Clinical Oncology group 0403) of SBRT in operable
patients.30
rapy for primary liver tumors. Retrospective and phase
oses Local control Toxicity
1 year 95% 10% grade ≥ 3HCC Child B
1 year 75% 18% grade ≥ 3HCC Child B
1 year 80% No grade ≥ 3
1 year 65% 16% grade ≥ 3HCC Child B
d A40 Gy/3 fx Child B 1 year 96% 18% grade ≥ 3HCC Child B
2 years 90–5% 10% grade ≥ 3
)40 Gy/5 fx (Child B) 2 years 90% No grade ≥ 3
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The started prospective phase III studies (ROSEL and
TARS) randomizing surgery with SBRT in operable stage IA
SCLC had difﬁculties recruiting patients and were closed.31,32
At this moment the only phase III study comparing SBRT
nd surgery is the ACOSOG Z4099-RTOG 1021 trial. This trials
ompares sublobar resection with or without brachytherapy (I
25 implant at the resection margin) in high risk stage IA-IB
SCLC.33
.  Lung  SBRT  with  intrafraction  control  of
umor  motion
ccuracy in the treatment of lung tumors with SBRT is one
f the main issues, and compensating techniques with gat-
ng and tracking can add an advantage to this treatments in
erms of toxicity. Early experience with Novalis Exactrac Adap-
ive Gating has been published for 34 patients.34 Peripheral
ung lesions were treated with 3 fractions of 15–20 Gy and cen-
ral lung lesions with 5 fractions of 10 Gy. Internal markers
ere implanted in all the patients with a 26% rate of pneumo-
orax. Two year local control was 93.8%. Clinical tolerance was
xcellent, and no acute or late lung grade 3 was observed.
Bibault35 reported 51 patients treated with SBRT with the
LTS without ﬁducials. The local control and overall survival
ate were, respectively, 92% and 85.5% at 1 year and 86% and
9.4% at 2 years. These efﬁcacy results are comparable with
ther published series using ﬁducials. Only 7 cases of grade
 and one grade 2 radiation pneumonitis were reported and
bviously there was no pneumothorax case. No rib fractures
ere observed but this study only included tumors distant of
t least 15 from the ribs. Indeed, due to the hypofractiona-
ion scheme and the high dose per fraction in SBRT, the ribs
ust be considered as organs at risk. In the literature, rib
racture occurs approximately in 40% of patients treated with
BRT and most reported risk factors for rib fractures are chest
all/tumor distance, female gender and maximum dose to 8cc
o chest wall.36
Although not the subject of this review, it is interesting
o note that SBRT has also an important role to play in the
reatment of patients with oligometastases. SBRT appears to
e an effective and well tolerated local therapy for patients
ith limited metastatic disease within the lung or the liver.
rospective phase I/II studies refer to 2-year local control rates
hat reach 92–96%, with very low toxicity related after SBRT
oses from 48 to 60 Gy in 3 fractions.37,38 Providing equiva-
ent local control to surgical resection, SBRT may also be an
lternative to surgery in patients with oligometastatic disease.
.  SBRT  for  liver  primary  tumors
rimary liver cancer is the world’ third most common cause
f cancer death and hepatocellular carcinoma (HCC) accounts
or 85–90% of them. Risk factors for HCC include hepatitis
 or C, alcohol ingestion and any cause of cirrhosis.39 This
nderlying liver disease and the fact that HCC tend to be mul-
ifocal or with vascular invasion, make many  patients with
iver tumors poor candidates for surgery, and only 30–40% of
he patients can beneﬁt from curative treatments. In selectedtherapy 1 8 ( 2 0 1 3 ) 387–396 391
patients, with early stage, adequate liver function (Child–Pugh
A), performance status of 0, single or 3 lesions < 3 cm,  and no
associated diseases, surgical resection can result in 5-year sur-
vival rates of 40–70% and liver transplantation can cure both,
the cancer and the underlying liver.40 In patients with asso-
ciated disease, early stage HCC and lesions < 3 cm away from
large vessels, radiofrequency ablation and alcohol injection
are also used as an alternative to surgery.
Cure with preserved liver function is a treatment goal and
liver function is an important component of treatment deci-
sions. Historically, radiation therapy has had a limited role in
the treatment of liver tumors because of the low tolerance
of the liver to radiation. The major dose-limiting concern is
the risk of radiation-induced liver disease (RILD), and pro-
gression of Child–Pugh class must be considered as an end
point of toxicity for those patients. However, because the func-
tional units of the liver parenchyma obey the parallel model
of radiobiology, a high dose radiation can be focally adminis-
tered if sufﬁcient normal tissue can be spared, and with SBRT
it is possible to treat safely small or moderated sized hepatic
tumors.
For HCC SBRT some speciﬁc considerations must be taken
into account: GTV target delineation has to rely on phase
arterial contrast CT or MRI imaging, the risk of microscopic
extension should contemplate CTV margins of at least 5 mm,
and in order to minimize toxicity it is imperative to use
tight margins in PTV, therefore ITV should be reduced with
restrictive or compensating techniques. Dose prescription
and dosimetric constraints must take into account patient’
Child–Pugh class score, and lesions size.
Blomgren, in 1991, ﬁrst used SBRT to treat liver malignan-
cies and since then retrospective and prospective studies have
demonstrated efﬁcacy and safety with local control rates in
the range of 70–90% at 1 year (Table 2). Because SBRT is relative
new, prospective data are quite scarce.16
7.  HHC  SBRT  prospective  studies
The ﬁrst prospective study came from Mendez-Romero in 2006
who treated 8 HCCs (37.5 Gy in 3 fractions of 12.5 Gy or 25 Gy
in 5 fractions of 5 Gy), with 1-year LC of 75% and severe tox-
icity only in a Child–Pugh B patient.41 Choi in 2006 treated 20
patients with HCCs (15 Child class A), with 50 Gy in 5 frac-
tions of 10 Gy, no episodes of severe toxicity were reported,
1-year LC of 80% and overall survival (OS) of 70%.42 Another
phase I study from Canada (Tse 2008) treated 31 HCCs, with a
median dose of 36 Gy (range 24–54 Gy), tumors were generally
large and half of the patients had large-vessel thrombosis.43
No patients developed grade 4/5 liver toxicity. One-year LC was
65% and OS of 48%. The University of Indiana conducted a
prospective study in 17 patients with HCCs.44,45 The dose was
escalated in Child–Pugh A patients from 36 Gy in 3 fractions of
12 Gy to 48 Gy in 3 fractions of 16 Gy. Two Child–Pugh B patients
developed grade 3 hepatic toxicity at 42 Gy in 3 fractions, so
subsequently these patients were treated with 40 Gy in 5 frac-
tions of 8 Gy. Only 12% of the patients with a Child–Pugh score
≤7 developed hematologic or hepatic dysfunction > grade I,
whereas 4 of 8 patients with score ≥ 8 developed progressive
liver failure.
d rad392  reports of practical oncology an
8.  HCC  SBRT  retrospective  studies
There are also several retrospective studies of interest.
Andolino, continuing with the study from the University of
Indiana, treated 60 patients with HCCs (36 Child–Pugh A and
24 Child–Pugh B), with a 2-year LC of 90% and OS of 67%.46
Size of the lesions (>6 cm)  and previous liver function were
limiting factors (Child–Pugh score ≥ 8) for toxicity, and those
patients should only be consider for SBRT as a “bridge therapy”
to transplant. SBRT as deﬁnitive therapy for those ineligible for
transplant should include 1–3 lesions, maximum tumor diam-
eter ≤ 6 cm,  and a Child–Pugh A–B score ≤ 7. Son also reported
the experience with 36 HCC patients treated with 30–39 Gy
in 3 fractions. 11% of the patients developed progressions of
Child–Pugh class when V18 Gy of > 800 ml.47
Lille experience in 2012 reported a high local control rate
(89% 1-year LC) in 42 patients treated for an HCC and six for a
cholangiocarcinoma.48 To track the lesions, they implemented
ﬁducials (2–6) around each lesion. A total dose of 40–45 Gy at
the 80% isodose was delivered. Local control rates at one and 2
years were 89% and 81% for the HCC. Overall survival and local
control rate for cholangiocarcinoma were 100% at 1 year. Toxic-
ity consisted mainly of nausea, abdominal pain and asthenia
and was correlated with the duration of treatment (p < 0.04).
12 patients presented with grade 3 or 4 gastro-intestinal side
effects. Half of them were gastrointestinal toxicities involving
lesions which were close to the digestive structures. Progno-
stic factors associated with better local control were lesion
size < 50 mm (p = 0.019), PTV volume < 200cc (p = 0.014) and a
delivered dose ≥ 45 Gy. Until now, SBRT appears to be a safe
way to treat liver tumors with little toxicity, if lesions at imme-
diate proximity of digestive structures are excluded.49
For cholangiocarcinomas both intra and extrahepatic sur-
gical resections have historically been considered the only
curative option. However, only about one-third of patients
present with resectable disease and for unresectable patients
the prognosis is particularly dismal with a median survival
of only 2–6 months. Single agent or combination chemother-
apy and conventionally fractionated radiotherapy seems to
be largely ineffective. Improved local control and survival
rates have been observed with higher radiotherapy doses sug-
gesting dose escalation strategies as a promising therapeutic
approach. SBRT experience in the treatment of unresectable
cholangiocarcinoma is limited. Twenty-seven patients with
unresectable cholangiocarcinoma (n = 26 Klatskin tumors and
one intrahepatic cholangiocarcinoma (IHCC) were treated
with SBRT.50 The dose schedule was 45 Gy in three fractions.
The median progression-free survival and overall survival
were 6.7 and 10.6 months, respectively. With a median
follow-up of 5.4 years, 6 patients had severe duodenal/pyloric
ulceration and 3 patients developed duodenal stenosis.
Early experience with Novalis Exactrac Adaptive Gating
in 13 HCC and 9 cholangiocarcinoma is presented in this
review and supports its accuracy, efﬁcacy and excellent tol-
erance. 11 Child–Pugh A HCC patients were treated with 3
fractions of 15–16 Gy and 2 Child–Pugh B with 10 fraction of
5 Gy. No acute or late grade ≥ 3 was observed. With a medium
follow up of 18 months, local control was 91.7%. In the follow
up, 4 patients developed intrahepatic progression with newiotherapy 1 8 ( 2 0 1 3 ) 387–396
lesions and 2 presented distant metastases. Nine patients with
Cholangiocarcinomas where also treated with SBRT and with
standard concurrent capecitabine as a neoadjuvant combined
treatment. The total dose was 50 Gy in 10 fractions. Toler-
ance was excellent and only one patient developed grade II
transaminitis. Of the 9 patients, 8 underwent surgery, one
patient progressed with liver metastases. All surgical margins
were tumor free. One year local control was 100% and median
survival was 17.67 months.
SBRT offers a safe and effective alternative for early stage
HCCs and should be considered for patients who  are poor
candidates for surgery or transplantation, patients with com-
promised liver function must be treated more  cautiously, and
randomized studies are warranted to compare the efﬁcacy of
SBRT with other treatment modalities.
9.  SBRT  in  prostate  cancer
Prostate cancer is the most frequent male cancer in developed
countries and radical prostatectomy and radiotherapy are
treatment approaches for most localized tumors. Radiothe-
rapy dose-escalation studies have shown a signiﬁcantly better
outcome (5-year disease control probability > 80%). Prostate
cancer is characterized by an ˛/  ˇ ratio = 1.4 Gy, lower than
that of most tumors or even of the late-responding normal
tissues surrounding the tumor: the rectum and the bladder
(˛/ˇ = 3–5 Gy).51 Thus, large treatment fractions (hypofrac-
tionation) may increase the tumor cell killing effect while
biologically protecting the surrounding late responding nor-
mal  tissues. Preliminary results of two pilot studies on
extreme hypofractionation SBRT (5 daily fractions of 6.7 and
7.25 Gy over 5 and 5–9 days, respectively) have been reported,
5-year biochemical disease control rates above 90%.52,53
Therefore, there is a need to test the effect on tolerance and
outcome of large fractions. A prospective multi-center phase
II study in France has been coordinated by Lartigau. The aim
was to demonstrate the feasibility of delivering a 3 × 6 Gy boost
after IMRT or 3D delivery of 46 Gy in intermediate risk tumors.
Seventy-two patients were included in less than 2 years in
4 participating centers (3 CyberKnife and 1 Linac). No acute
toxicity was recorded and feasibility was excellent. Six Cen-
ters in France will participate in the new upcoming phase III
PACE trial on the role of exclusive SBRT compared to radical
prostatectomy.
10.  SBRT  in  reirradiation
Most SBRT indications that have previously been described
concern patients who are not amenable to surgery. For
head-and-neck or pelvic tumors that were ﬁrst treated with
radiation therapy, SBRT enables to consider reirradiation,
which was otherwise clearly not an option.54 Indeed, most of
the recurrences occur in the previously irradiated ﬁeld and
it is impossible in traditional radiotherapy to deliver enough
dose-intensity to control the disease. The surgery is often
impossible due to the previous irradiation and the location
of the recurrence.
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1.  Head  and  neck  SBRT  irradiation
eirradiation is an alternative for patients who are not candi-
ates for surgical salvage although has a signiﬁcant challenge
egarding toxicity.55 Three-year survival rates of 13–22% have
een reported with external beam RT alone.56 Results from
hase I/II trials have also demonstrated the beneﬁt of reirra-
iation with concurrent chemotherapy over observation.57,58
merging data also support the safety of conformal delivery
echniques, like intensity modulated radiation therapy, with
otentially less treatment-related toxicity and local control
mprovement.59,60
SBRT is an attractive treatment modality for HNC reirradi-
tion. The primary beneﬁts of SBRT relative to conventional
e-irradiation are shorter treatment times and decreased
oxicity, which are achieved without compromising clinical
utcomes.61,62
Currently an on-going phase II trial in Lille is leaded for
ecurrent head and neck squamous cell carcinoma, and pre-
iminary experience was already published.63 Forty patients
ere treated between June 2007 and January 2010 for a median
umor size of 29 mm.  A dose of 36 Gy was delivered in 6 frac-
ions. 14 patients received a concurrent infusion of cetuximab.
fter 25.6 months of median follow-up, 15 patients experi-
nced a complete response and overall objective response was
9.4%. 20 presented with disease progression but only 3 with
ocal relapse. 4 patients experienced a grade 3 toxicity but no
arotid blowout was observed. This was explained by the fact
hat tumors invading more  than one third of the carotid were
ot treated. Median overall survival was 13.6 months which is good result considering the poor prognostic of these patients.
SBRT boost technique can be also a highly efﬁcacious dose
scalation modality in terms of local control. However, high
ig. 3 – Follow up with radiological evaluation of response after S
rterial contrast enhancement is included in the new RECIST crittherapy 1 8 ( 2 0 1 3 ) 387–396 393
late complications have been observed and should be indi-
cated only in selective cases because large treatment volumes
treated with very high fractional doses have been related with
high risk of developing late toxicities.64
12.  Pelvic  SBRT  reirradiation
Pelvic tumor recurrence is usually treated by surgery but in
case of lateral pelvic invasion recurrence or proximity of the
iliac vessel, local treatment cannot be achieved. Without treat-
ment, local progression often causes pain and impacts the
quality of life. Since June 2007, 16 patients with pelvic recur-
rence were reirradiated with the CyberKnife.65 Primary tumors
were rectal cancer (4 patients), anal canal (6 patients), uterine
cervix cancer (4 patients), endometrial cancer (1 patient) and
bladder carcinoma (1 patient). The prescribed dose was36 Gy
in 6 fractions. Of 8 patients, who had sciatic pain before treat-
ment, 4 patients reported an improvement. The local control
rate at 1 year was 51.4%. The treatment was well tolerated and
we observed no grade 3 toxicity.
Reirradiation is often a complex situation in which there is
no alternative and SBRT seems to be a safe and efﬁcient option
to treat tumor recurrences even if not in a curative intent. Nev-
ertheless, further prospective studies are needed to precise the
indications and the toxicity proﬁle for these treatments.
13.  Follow-up  after  SBRTDose distribution in SBRT is extremely different from con-
ventional radiotherapy. Early and late reactions can also be
very different. Radiologic aspect after SBRT can be sometimes
very difﬁcult to analyze. Indeed, RECIST criteria, which are
BRT treatment for Hepatocellullar carcinoma. Reduction of
eria of response for HCC.
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based on the change of lesion size, appear to be inappropri-
ate. After SBRT, lung condensation can mimic  an increase of
size of the lesion although there is no recurrence. Bibault66
described the semiology that should lead to suspicion of recur-
rence: localization in continuation with treated lesion, pleural
effusion, disappearance of initial bronchiectasis and mor-
phological modiﬁcations of ﬁbrosis contours. Timing of the
appearance of these images is essential: early reactions occur
between six and nine months late changes, after 12 months,
including size or contours modiﬁcations with enlarging opac-
ity can be considered high-risk CT changes and recurrent
disease should be suspected if seen with SUVmax ≥ 5 on PET,
with a high predictive value.67
The paradigms of evaluation of liver lesions have been
modiﬁed in regard of radiologic aspect after novel targeted
therapies. For example, modiﬁed RECIST criteria have been
developed for HCC. Jarraya68 showed that RECIST criteria could
lead to a misinterpretation of some lesions, especially in case
of tumors that become necrotic after treatment. They sug-
gest using lobular enhancement, total necrosis and rimming
enhancement in addition to RECIST criteria (Fig. 3). Metabolic
imaging like FDG-PET could also be useful but has not been
evaluated in this indication. If considered, FDG-PET imaging
must not be realized before a minimal delay of 6 months.
Indeed, initial inﬂammatory reactions caused by high doses
per fraction/SBRT can be responsible for false-positive results;
however, some publications suggest metabolic response after
SBRT could be a good prognostic factor of loco-regional
relapse.69 Currently, the optimal supervision after SBRT is not
known. Follow-up must be carried by radiologists who are
accustomed to SBRT post-therapeutic aspects.
14.  Conclusion
Stereotactic body radiation therapy is a recent radiotherapy
technique, which has quickly developed because of its excel-
lent results in terms of tolerance and its high loco-regional
control rates. The implementation of SBRT in routine requires
a careful considering of organ motion. Gating and Tracking are
effective ways to do so, and the development of new technolo-
gies such as X-Sight Lung have made it become less invasive.
Due to the hypofractionated scheme, the physician must pay
attention to new dosimetric constraints and new radiologic
post-treatment aspects. Although there seems to be a link
between BED and local control, new radiobiological models are
needed to assess the optimal fractionation and dose scheme.
These limitations imply that SBRT should only be conducted
by experienced multidisciplinary teams at the time being.
Some SBRT indications, such as lung primary tumors treat-
ments, have become a standard of care for inoperable patients.
SBRT seems to be effective in many  other indications in cura-
tive or palliative intent such as primary liver tumors. Novel
indications and strategies are currently emerging, for example
prostate cancer treatment or associations of chemotherapy
and SBRT.
Currently, SBRT is mainly used when there is no other ther-
apeutic alternative for the patient. This is due to the lack
of randomized trials in these settings. However, the results
1iotherapy 1 8 ( 2 0 1 3 ) 387–396
shown in retrospective studies let us hope to impose SBRT as
a new standard of care for many  patients in the next few years.
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